BRPI0509894A - composições farmacêuticas compreendendo um amido anfifìlico - Google Patents

composições farmacêuticas compreendendo um amido anfifìlico

Info

Publication number
BRPI0509894A
BRPI0509894A BRPI0509894-7A BRPI0509894A BRPI0509894A BR PI0509894 A BRPI0509894 A BR PI0509894A BR PI0509894 A BRPI0509894 A BR PI0509894A BR PI0509894 A BRPI0509894 A BR PI0509894A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
starch
compositions
excipients
amphiphilic starch
Prior art date
Application number
BRPI0509894-7A
Other languages
English (en)
Inventor
John Staniforth
Naresh Talwar
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of BRPI0509894A publication Critical patent/BRPI0509894A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIçõES FARMACêUTICAS COMPREENDENDO UM AMIDO ANFIFìLICO. A presente invenção refere-se a liberação controlada ou sustentada de composições farmacêuticas sólidas, a excipientes farmacêuticos para uso na fabricação de tais composições e a processos de produção de tais composições e excipientes. Os excipientes de liberação controlada ou sustentada incluem um excipiente de controle de liberação contendo um amido anfifílico.
BRPI0509894-7A 2004-04-14 2005-04-14 composições farmacêuticas compreendendo um amido anfifìlico BRPI0509894A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0408308.5A GB0408308D0 (en) 2004-04-14 2004-04-14 Pharmaceutical compositions
PCT/GB2005/050051 WO2005099674A1 (en) 2004-04-14 2005-04-14 Pharmaceutical compositions comprising an amphiphilic starch

Publications (1)

Publication Number Publication Date
BRPI0509894A true BRPI0509894A (pt) 2007-10-30

Family

ID=32320811

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509894-7A BRPI0509894A (pt) 2004-04-14 2005-04-14 composições farmacêuticas compreendendo um amido anfifìlico

Country Status (15)

Country Link
US (1) US20080171083A1 (pt)
EP (1) EP1734932A1 (pt)
JP (1) JP2007532620A (pt)
KR (1) KR20070053163A (pt)
CN (1) CN1968683A (pt)
AU (1) AU2005232442A1 (pt)
BR (1) BRPI0509894A (pt)
CA (1) CA2562806A1 (pt)
GB (1) GB0408308D0 (pt)
IL (1) IL178611A0 (pt)
MX (1) MXPA06011860A (pt)
NO (1) NO20065190L (pt)
NZ (1) NZ550648A (pt)
SG (1) SG152240A1 (pt)
WO (1) WO2005099674A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
HU230828B1 (en) 1999-10-29 2018-08-28 Euro Celtique Sa Controlled release hydrocodone formulations
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
JP4389205B2 (ja) * 2002-02-06 2009-12-24 宇部興産株式会社 ４−アミノキナゾリン化合物の製法
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US7993678B2 (en) * 2005-09-26 2011-08-09 Novozymes Biopolymer A/S Hyaluronic acid derivatives
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP2007360B1 (en) 2006-04-03 2014-11-26 Isa Odidi Controlled release delivery device comprising an organosol coat
CA2648495C (en) * 2006-04-26 2016-07-05 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
ES2288117B1 (es) * 2006-05-08 2008-12-01 Combino Pharm, S.L. Composicion farmaceutica solida de gabapentina.
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
WO2009043914A1 (en) * 2007-10-05 2009-04-09 Krka, D.D., Novo Mesto Multi particulate matrix system containing galantamine
EP2044933A1 (en) * 2007-10-05 2009-04-08 KRKA, D.D., Novo Mesto Multi particulate matrix system containing galantamine
DK2344495T3 (en) 2008-10-07 2015-02-02 Actelion Pharmaceuticals Ltd TRICYCLIC OXAZOLIDINON ANTIBIOTIC COMPOUNDS
EP2396311A2 (fr) * 2009-02-13 2011-12-21 Ipsen Pharma S.A.S. Composition pharmaceutique solide contenant le 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta(c)chromen-3-yl sulfamate et polymorphes de ce dernier
US20100215758A1 (en) * 2009-02-25 2010-08-26 Joar Opheim Effervescent nutritional and/or dietary supplement composition
MX2012012991A (es) 2010-05-11 2012-11-30 Cima Labs Inc Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
WO2013077847A1 (en) * 2011-11-21 2013-05-30 Handa Pharmaceuticals, Llc Oral dosage forms for delivering gabapentin
WO2013183422A1 (ja) * 2012-06-08 2013-12-12 理研ビタミン株式会社 ステアロイル乳酸ナトリウム製剤
CA2888278A1 (en) * 2012-10-15 2014-04-24 Isa Odidi Oral drug delivery formulations
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
KR102370961B1 (ko) 2013-12-31 2022-03-07 필립모리스 프로덕츠 에스.에이. 액체 전달 물질을 가지는 흡연 물품
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
CN110251686B (zh) * 2019-06-28 2021-02-19 华南理工大学 一种淀粉基两亲性自组装载体材料及其制备方法与应用
EP3818975A1 (en) * 2019-11-08 2021-05-12 Roquette Freres Use of sodium octenyl-succinate starches as a binder in continuous wet granulation
EP3819336A1 (en) * 2019-11-08 2021-05-12 Roquette Freres Use of octenyl-succinate starches as a binder in wet granulation
WO2022205328A1 (zh) * 2021-04-01 2022-10-06 李冠天 壬烯基琥珀酸酐改性淀粉及其制备方法与应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1405088A (en) 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
EP0147780A3 (en) 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
ATE61935T1 (de) 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
JP3114758B2 (ja) * 1991-02-13 2000-12-04 東ソー株式会社 ポリフェニレンスルフィド樹脂組成物
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
BE1009380A3 (nl) * 1995-03-14 1997-03-04 Universiteit Gent Lab Voor Far Stabiliserend samenstelling voor suspensie.
DE19619837B4 (de) * 1996-05-17 2007-03-08 Beiersdorf Ag Kosmetische oder pharmazeutische Zubereitungen mit vermindertem Klebrigkeitsgefühl
JP4028642B2 (ja) * 1997-10-07 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳化粉末の製造方法
ATE238772T1 (de) * 1997-10-07 2003-05-15 Eisai Co Ltd Verfahren zur herstellung von emulgiertem puder
ATE350014T1 (de) * 1997-10-31 2007-01-15 Nat Starch Chem Invest Verwendung eines enzymatisch behandelten stärkederivates als einkapselungsmaterial
CA2358062C (en) * 1998-12-24 2006-12-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
DE10135694A1 (de) * 2001-07-21 2003-02-06 Supramol Parenteral Colloids Amphiphile Stärke-und Hydroxyethylstärke-Konjugate
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
JP2003213038A (ja) * 2001-11-16 2003-07-30 Natl Starch & Chem Investment Holding Corp デンプンを含有するフィルム
EP1513504A1 (en) * 2002-06-07 2005-03-16 Ranbaxy Laboratories, Ltd. Sustained release oral dosage forms of gabapentin
US8252322B2 (en) * 2003-06-03 2012-08-28 Corn Products Development, Inc. Delivery system with increased bioavailability
CN1270717C (zh) * 2003-11-28 2006-08-23 李思成 加兰他敏缓释制剂及其制备方法

Also Published As

Publication number Publication date
GB0408308D0 (en) 2004-05-19
CA2562806A1 (en) 2005-10-27
NZ550648A (en) 2009-09-25
IL178611A0 (en) 2007-02-11
JP2007532620A (ja) 2007-11-15
WO2005099674A1 (en) 2005-10-27
EP1734932A1 (en) 2006-12-27
CN1968683A (zh) 2007-05-23
AU2005232442A1 (en) 2005-10-27
US20080171083A1 (en) 2008-07-17
KR20070053163A (ko) 2007-05-23
SG152240A1 (en) 2009-05-29
MXPA06011860A (es) 2007-01-25
NO20065190L (no) 2007-01-11

Similar Documents

Publication Publication Date Title
BRPI0509894A (pt) composições farmacêuticas compreendendo um amido anfifìlico
CY1122575T1 (el) Φαρμακοτεχνικες μορφες διστρωματικου δισκιου
HN2003000196A (es) Derivados de indolinfenilsulfonamida
UY30578A1 (es) Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones
BRPI0514731A (pt) derivados de pirimidina
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
NO2015011I2 (no) Dasabuvir eller et salt derav, inkludert dasabuvir natriumsalt
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
ECSP077271A (es) Derivados de pirimidina
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
BRPI0512330A (pt) derivados de pirazol-pirimidina
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
DK1427708T3 (da) Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme
UY30712A1 (es) Nuevos derivados de 1, 4-benzotiepina-1, 1-dioxido sustituidos con fluor, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.
BRPI0511616A (pt) compostos
DOP2002000429A (es) Imidazotriazinas
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
TW200621313A (en) Pharmaceutical compositions
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
BRPI0607413A2 (pt) composição farmacêutica compreendendo derivados de indolilmaleimida
CY1113482T1 (el) Αναστολεις υποδοχεα σιγμα
NO20062824L (no) 1,3-Difenylprop-2-en-1-on-avledete forbindelser, fremgangsmater for fremstilling derav, samt anvendelse av samme

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PHARMAKODEX LIMITED (GB)

Free format text: TRANSFERIDO DE: VECTURA LIMITED

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.